Both Novus Therapeutics Inc. (NASDAQ:NVUS) and aTyr Pharma Inc. (NASDAQ:LIFE) are Biotechnology companies, competing one another. We will contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Novus Therapeutics Inc. | N/A | 0.00 | 11.60M | -1.37 | 0.00 |
| aTyr Pharma Inc. | N/A | 0.00 | 39.67M | -1.33 | 0.00 |
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Novus Therapeutics Inc. and aTyr Pharma Inc.
Profitability
Table 2 demonstrates the return on equity, return on assets and net margins of Novus Therapeutics Inc. and aTyr Pharma Inc.
| Net Margins | Return on Equity | Return on Assets | |
| Novus Therapeutics Inc. | 0.00% | -55.5% | -51.7% |
| aTyr Pharma Inc. | 0.00% | -78.1% | -53.6% |
Risk and Volatility
A beta of 0.82 shows that Novus Therapeutics Inc. is 18.00% less volatile than Standard & Poor’s 500. Competitively, aTyr Pharma Inc.’s 187.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.87 beta.
Liquidity
Novus Therapeutics Inc. has a Current Ratio of 10.7 and a Quick Ratio of 10.7. Competitively, aTyr Pharma Inc.’s Current Ratio is 5.4 and has 5.4 Quick Ratio. Novus Therapeutics Inc.’s better ability to pay short and long-term obligations than aTyr Pharma Inc.
Analyst Ratings
The next table highlights the shown recommendations and ratings for Novus Therapeutics Inc. and aTyr Pharma Inc.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Novus Therapeutics Inc. | 0 | 0 | 0 | 0.00 |
| aTyr Pharma Inc. | 0 | 2 | 0 | 2.00 |
Competitively aTyr Pharma Inc. has a consensus price target of $0.88, with potential upside of 80.70%.
Insider & Institutional Ownership
The shares of both Novus Therapeutics Inc. and aTyr Pharma Inc. are owned by institutional investors at 52.9% and 55.7% respectively. About 0.8% of Novus Therapeutics Inc.’s share are owned by insiders. Comparatively, aTyr Pharma Inc. has 0.4% of it’s share owned by insiders.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Novus Therapeutics Inc. | -20.46% | -33.01% | -39.07% | -56.67% | -36.7% | -32.02% |
| aTyr Pharma Inc. | -6.49% | -9.83% | -23.17% | -41.75% | -85.23% | -83.54% |
For the past year Novus Therapeutics Inc.’s stock price has smaller decline than aTyr Pharma Inc.
Summary
On 5 of the 7 factors Novus Therapeutics Inc. beats aTyr Pharma Inc.
Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.
